A large observational study of results in routine clinical practice showed that visual acuity outcomes 12 months after Aflibercept or Ranibizumab treatment did not differ, and neither did the number of injections required for each agent.
The only factor that predicted visual outcomes one year after nAMD diagnosis was baseline visual acuity, which maintained its predictive ability five years after diagnosis. Visual acuity increased more frequently in women.
In an 84-year-old woman with AMD and acute deterioration in vision, the oral antioxidant supplement Resvega led to regression of subretinal fluid and eliminated the need for intravitreal injection of an anti-VEGF agent over the course of 9 months.
An optical coherence tomography study found that, after three monthly treatments,aAflibercept was 7 times more effective than ranibizumab in resolving serous pigment epithelium detachment, though neither treatment improved visual acuity in these patients to a statistically significant degree.
Vitrectomy plus subretinal injection of tissue plasminogen activator (tPA) reduced scar area moreso than pneumatic displacement plus intravitreal injection of tPA. Visual acuity improved noticeably after both of these treatments, but not after treatment with pneumatic displacement alone.
Age-related macular degeneration (AMD) was 72% more likely to develop in end-stage renal disease patients than in control subjects and 74% more likely to develop in peritoneal dialysis patients than in hemodialysis patients.
After 12 months of follow-up, a Japanese team found a trend toward greater BCVA improvement in the Eylea group than in the Lucentis group but no statistically significant differences between groups in BCVA or central foveal thickness.
No difference in the superficial capillary plexuses was found in cases of diabetic macular edema that responded well to anti-vascular endothelial growth factor as opposed to those that didn't, but poor responders had more damage and microaneurysms in the deep capillary plexus.